cxcr5 modified egfr chimeric antigen receptor autologous t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2019 (NCT05060796)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Epidermal growth factor receptor erbB1Immunity, passive
EGFR immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04153799 | Phase 1 | Nov 30, 2019 | Guangzhou Bio-gene Technology Co., Ltd., Sun Yat-Sen University |
| NCT05060796 | Early Phase 1 (Phase 1) | Sep 1, 2019 | Guangzhou Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou Bio-gene Technology Co., Ltd. | For profit | 1 | 0 | 1 | 2019 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1